<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493272</url>
  </required_header>
  <id_info>
    <org_study_id>20070037</org_study_id>
    <nct_id>NCT00493272</nct_id>
  </id_info>
  <brief_title>Dilutional Coagulopathy in Patients Undergoing Elective Surgery</brief_title>
  <official_title>Fibrinogen vs Placebo for Improvement of Clot Strength</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Fenger-Eriksen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to perform a comprehensive description of haemostasis&#xD;
      parameters before and after haemodilution with Hydroxyethyl starch (HES) following acute&#xD;
      bleeding during elective surgery. Moreover the study aims to test the in vivo haemostatic&#xD;
      potential of fibrinogen concentrate in dilutional coagulopathy caused by HES in a clinical,&#xD;
      prospective, placebo-controlled randomised setup.&#xD;
&#xD;
      We hypothesise; a) A coagulopathy is induced following in vivo haemodilution; b) the&#xD;
      coagulopathy is improved or partially improved by fibrinogen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Hydroxyethyl starch (HES) is a group of artificial colloid solutions widely used&#xD;
      for plasma expansion and volume resuscitation. HES consist of branched chains of hydroxylated&#xD;
      glucose molecules defined by average molecular weight, degree of hydroxyethylation, and C2/C6&#xD;
      ratio. Several clinical reports and in vitro experiments have documented an impaired&#xD;
      coagulation system induced by haemodilution with HES and other colloid plasma expanders. The&#xD;
      exact mechanisms responsible for HES induced coagulopahty are not fully understood although&#xD;
      reduced levels of von Willebrand factor (vWF), acquired platelet dysfunction, reduced factor&#xD;
      VIII levels, and dysfunctional fibrinogen polymerization seems to reflect an important aspect&#xD;
      of the pathogenesis.&#xD;
&#xD;
      Experimental laboratory studies performed in our centre and verified by several other&#xD;
      research groups have shown successful reversal of the colloid plasma expander induced&#xD;
      coagulopathy by fibrinogen concentrate.10-13 So far, the present knowledge are based on&#xD;
      laboratory experiments and animal studies. Hence, it appears desirable to perform a&#xD;
      comprehensive description of haemostasis parameters following HES induced dilutional&#xD;
      coagulopathy in an acute clinical bleeding situation.&#xD;
&#xD;
      Materials and Methods&#xD;
&#xD;
      Study design: Clinical, prospective, double-blind, randomised, place-controlled trial. Blood&#xD;
      samples:&#xD;
&#xD;
      Primary end point:&#xD;
&#xD;
      Dynamic whole blood clot formation&#xD;
&#xD;
      Secondary end points:&#xD;
&#xD;
      A) Single coagulation factor activities B) Platelet function C) Whole blood clot stability.&#xD;
      D) Thrombin generation&#xD;
&#xD;
      Perspectives:&#xD;
&#xD;
      Serious surgical and traumatic bleedings are common and associated with a high mortality&#xD;
      rate. The present study can significantly contribute to our overall understanding of the&#xD;
      mechanisms involved in HES induced dilutional coagulopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic whole blood clot formation.</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A) Single coagulation factor activities B) Platelet function C) Whole blood clot stability. D) Thrombin generation.</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nacl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrinogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fibrinogen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrinogen</intervention_name>
    <description>Fibrinogen behandling</description>
    <arm_group_label>Fibrinogen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Active drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years&#xD;
&#xD;
          -  Indication for performing cystectomia&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uses of acetyl-salicylic or non-steroid anti-inflammatory drugs 2 days prior to blood&#xD;
             sampling.&#xD;
&#xD;
          -  Abnormal preoperative coagulations parameters (Platelets, PP, APTT, D- dimer,&#xD;
             Fibrinogen, AT, TT)&#xD;
&#xD;
          -  Disseminated cancer and/or bone metastasis&#xD;
&#xD;
          -  Medical history of ischemic heart disease, claudicatio, or arteriosclerosis&#xD;
&#xD;
          -  Medical history of previous thrombo-embolic event&#xD;
&#xD;
          -  Renal failure defined as clinical relevant abnormal levels of creatinine&#xD;
&#xD;
          -  Liver failure defined as clinical relevant abnormal levels of ALAT&#xD;
&#xD;
          -  Hypersensibility to Voluven, Haemocomplettan or ingredients&#xD;
&#xD;
          -  Fertile women not using safe contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Else TÃ¸nnesen, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Department of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Anaesthesiology</name>
      <address>
        <city>DK-8200 Aarhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg. 1998 Nov;87(5):989-93. doi: 10.1097/00000539-199811000-00002.</citation>
    <PMID>9806670</PMID>
  </reference>
  <reference>
    <citation>Damon L, Adams M, Stricker RB, Ries C. Intracranial bleeding during treatment with hydroxyethyl starch. N Engl J Med. 1987 Oct 8;317(15):964-5. doi: 10.1056/NEJM198710083171517. No abstract available.</citation>
    <PMID>2442613</PMID>
  </reference>
  <reference>
    <citation>Baldassarre S, Vincent JL. Coagulopathy induced by hydroxyethyl starch. Anesth Analg. 1997 Feb;84(2):451-3. doi: 10.1097/00000539-199702000-00040. No abstract available.</citation>
    <PMID>9024047</PMID>
  </reference>
  <reference>
    <citation>de Jonge E, Levi M, Buller HR, Berends F, Kesecioglu J. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med. 2001 Nov;27(11):1825-9. doi: 10.1007/s001340101107. Epub 2001 Sep 26.</citation>
    <PMID>11810130</PMID>
  </reference>
  <reference>
    <citation>Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sorensen B. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth. 2005 Mar;94(3):324-9. doi: 10.1093/bja/aei052. Epub 2004 Dec 17.</citation>
    <PMID>15608046</PMID>
  </reference>
  <reference>
    <citation>Fenger-Eriksen C, Ingerslev J, Sorensen B. Coagulopathy induced by colloid plasma expanders--search for an efficacious haemostatic intervention. Acta Anaesthesiol Scand. 2006 Aug;50(7):899-900. doi: 10.1111/j.1399-6576.2006.01054.x. No abstract available.</citation>
    <PMID>16879481</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Fenger-Eriksen</investigator_full_name>
    <investigator_title>PhD MD</investigator_title>
  </responsible_party>
  <keyword>Blood coagulation disorder, acquired</keyword>
  <keyword>Hemodilution</keyword>
  <keyword>Fibrinogen</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>HES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

